MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Harrow Health Operating Expenses 2011-2026 | HROW
Annual Operating Expenses Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 174 M | 142 M | 90.1 M | 61.3 M | 52.6 M | 33.7 M | 35.2 M | 30.1 M | 25.4 M | 25.7 M | 19.3 M | 10.7 M | 7.7 M | 4.28 M | 939 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 174 M | 939 K | 47.5 M |
Quarterly Operating Expenses Harrow Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.2 M | 36.1 M | 43.5 M | - | 35.9 M | 34.9 M | 31 M | - | 22.5 M | 21.1 M | 16.6 M | - | 16.2 M | 15.1 M | 14.1 M | - | 17.5 M | 9.55 M | 8.76 M | - | 9.11 M | 8.07 M | 8.82 M | - | 13.1 M | 9.06 M | 8.95 M | - | 7.2 M | 6.85 M | 6.58 M | - | 5.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.5 M | 5.84 M | 17.8 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.11 | 4.27 % | $ 119 M |  Canada |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
154 M | $ 2.66 | 2.47 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
107 M | $ 5.19 | 25.54 % | $ 335 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
2.6 M | $ 0.58 | 2.89 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.18 | -8.73 % | $ 58.8 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.67 | 5.32 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.69 | -2.47 % | $ 445 M | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 12.24 | 2.9 % | $ 869 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.63 | -1.66 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 2.96 | 3.1 % | $ 390 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.41 | 2.55 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.9 | 0.08 % | $ 21 M | USA |
 |
Perrigo Company plc
PRGO
|
2.62 B | $ 11.61 | 1.98 % | $ 1.61 B | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.55 | 1.31 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
9.82 M | $ 2.24 | 0.94 % | $ 23.4 M | USA |
 |
Veru
VERU
|
44 M | $ 2.67 | 5.95 % | $ 360 M | USA |
 |
Viatris
VTRS
|
5.67 B | $ 14.7 | -1.31 % | $ 17.6 B | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 22.6 | 2.26 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
104 M | $ 4.77 | 2.14 % | $ 144 M | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 0.8 | 3.77 % | $ 3.45 M | USA |
 |
SCYNEXIS
SCYX
|
67.5 M | $ 0.77 | 2.75 % | $ 36.8 M | USA |
 |
Solid Biosciences
SLDB
|
130 M | $ 6.15 | 3.19 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.69 | -2.18 % | $ 3.34 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
1.52 B | $ 7.51 | 2.04 % | $ 4.64 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |